DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Fedovapagon is an investigational drug.
There have been 4 clinical trials for Fedovapagon. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.
The most common disease conditions in clinical trials are Nocturia, Prostatic Hyperplasia, and Hyperplasia. The leading clinical trial sponsors are Vantia Ltd and [disabled in preview].
There are six US patents protecting this investigational drug and one hundred and seventeen international patents.
Recent Clinical Trials for Fedovapagon
|Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)||Vantia Ltd||Phase 2/Phase 3|
|A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval||Vantia Ltd||Phase 1|
|Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon||Vantia Ltd||Phase 1|
Top disease conditions for Fedovapagon
Top clinical trial sponsors for Fedovapagon
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Fedovapagon||Start Trial||Condensed azepines as vasopressin agonists||Ferring BV (Hoofddorp, NL)||Start Trial|
|Fedovapagon||Start Trial||Fused azepine derivatives and their use as antidiuretic agents||Ferring BV (Hoofddorp, NL)||Start Trial|
|Fedovapagon||Start Trial||Condensed azepines as vasopressin agonists||Vantia Limited (GB)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|